ArticleBriefings in bioinformatics2026
MAPLE: interpretable deep learning identifies selective antimicrobial peptides using joint evolutionary-physicochemical analysis.
Article in Briefings in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Antimicrobial peptides (AMPs) are promising alternatives to conventional antibiotics, yet early translation is often hindered by the perceived coupling between antibacterial potency and mammalian toxicity. This assumption complicates prioritization: highly active candidates are frequently suspected to be hemolytic, while existing multi-task predictors rarely reveal where selectivity resides in sequence space. Here, we present Multifunctional AMP Learning Engine (MAPLE), an interpretable dual-stream framework for AMP identification and systematic category-specific functional profiling across 14 activity categories directly from peptide sequences. MAPLE combines protein language model embeddings with explicit physicochemical descriptors, enabling robust task-specific prediction under severe label imbalance. Across the benchmark dataset and a sequence-non-overlapping independent validation set, MAPLE achieves consistently well-balanced performance, including on low-prevalence but clinically relevant endpoints. Building on this predictive basis, we conduct systematic k-mer enrichment to map motif-level selectivity and show that potency-hemolysis coupling is motif-regime-dependent rather than universal. Motifs most strongly enriched for antibacterial activity exhibit reduced hemolytic overlap and occupy a physicochemical regime characterized by moderate cationicity, lower hydrophobicity, and higher amphipathicity. We further provide a proof-of-concept prioritization workflow leveraging antibacterial-selective motifs, with structural modeling yielding conformations consistent with amphipathic α-helices. Despite limitations of predominantly binary annotations and incomplete structural integration, MAPLE offers reproducible sequence-level hypotheses and prioritization principles to support the engineering of potent and safer AMPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.